Bevacizumab 1+3 pattern takes shape, Qilu, Xinda, Luye "bright move"

On May 26, 2021, AstraZeneca China announced that it has obtained the anti-tumor biopharmaceutical Boyouno (bevacizumab injection) from Boan Biologics, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China.
Exclusive marketing rights in the market
.

As soon as the news came out, it immediately attracted a lot of attention from the industry

According to the previous Frost & Sullivan report forecast, with the launch of the first bevacizumab biosimilar drug, the Chinese market will increase to 6.
4 billion yuan in 2023 and reach 9.
9 billion yuan in 2030
.

Boyouno, a subsidiary of Luye Pharmaceuticals, is the third domestically produced bevacizumab.

Qilubevacizumab temporarily ranks first in sales

With more and more players, how can latecomers catch up?

It is worth noting that Bevacizumab, a subsidiary of Luye Pharmaceutical Holdings, has only been approved for listing for more than 20 days
.

On May 7, 2021, Boan Bio's bevacizumab injection (trade name: Boyouno) was officially approved for listing in China

Bevacizumab was originally developed by Roche and is one of its super heavyweight oncology "troikas"
.

According to data, the drug is used to treat a variety of malignancies including non-small cell lung cancer, metastatic colorectal cancer, glioma, renal cell carcinoma, cervical cancer and epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

A few days ago, a PDB drug sales TOP 200 in the first quarter of 2021 showed that Qilu Pharmaceutical's bevacizumab (trade name: Enda), which was launched in December 2019, ranked 15th
.

According to reports, Qilu Pharmaceutical's Encore had annual sales of 1.

       In 2004, Avastin was listed in the United States.
In 2018, its global sales revenue was 7 billion U.
S.
dollars, ranking seventh in the global best-selling drug list in 2018
.

In 2010, Avastin was approved in China, and its sales in China in 2018 exceeded RMB 2 billion

       Before entering the national medical insurance catalogue in 2017, the median bid price of bevacizumab was 5253 yuan (100mg/bottle).
After medical insurance negotiations, the price of the drug was reduced to 1998 yuan (100mg/bottle); in 2018, Bevacizumab Valbizumab was further reduced to 1934 yuan (100mg/bottle), and the reimbursement ratio was as high as 70% to 90%, and the pressure of patients to pay was relieved
.

       Qilu Pharmaceutical's Enta is the first domestically-made bevacizumab approved for marketing.
After the listing, Enta's winning bid in 2020 is 1198 yuan, which is more than 700 yuan cheaper than the original drug Anvatin
.

Cinda's Bevacizumab (trade name: Dayotong) was approved for marketing in June 2020, half a year later than Qilu's Anta

       With the successive launch of domestic generic drugs, various companies have secretly competed on the price of bevacizumab.
For latecomers, they need to have certain advantages in terms of price and channels in order to break through
.

       The wind is screaming, the grass and trees are all soldiers

       Pharmaceutical companies take precautions and take the lead in "grabbing the beach"

       Luye Pharma chose to cooperate with AstraZeneca to transfer Boyouno’s exclusive marketing rights in 21 provinces, cities, and autonomous regions and counties markets in mainland China.
It seems that it also clearly sees the current competitive landscape
.

For its bevacizumab, the main target is the unsatisfied county market, and it can also seize a certain market share

       Due to changes in the domestic pharmaceutical environment, the county market has also become a territory for many pharmaceutical companies to compete for
.
For example, AstraZeneca has been in the county market earlier, mainly to promote its own products
.
It is understood that as of the end of April 2021, AstraZeneca's team in the county market has reached 4,000 people
.

       In addition to this cooperation with Luye Pharma, in March this year, AstraZeneca also took advantage of the county market to win the promotion of Junshi Bio-PD-1 in non-core markets in mainland China, and the subsequent approval of urothelium for listing Exclusive nationwide promotion rights for cancer indications
.

       With the continuous deepening of the volume procurement policy, multinational pharmaceutical companies have moved frequently in China this year.
Many pharmaceutical companies are stripping non-core assets, or optimizing product lines, and transforming and upgrading
.
Relying on its channel advantage, one of AstraZeneca's transformation directions in China seems to be to become a domestic contract sales organization ("CSO")
.

       In addition, it has been rumored that biopharmaceuticals will be purchased in quantities.
However, since the centralized procurement of biopharmaceuticals is more complicated and difficult, there has been no major move yet
.
At the beginning of 2021, CDE issued the "Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars (Draft for Comment)", and proposed the concept of similarity evaluation of biosimilars.
This policy is also considered to be similar to the consistency of generic drugs.
Evaluation, the industry expects that the centralized procurement of biopharmaceuticals is only a matter of time
.

       In January 2020, Wuhan has started piloting centralized insulin procurement
.
A few days ago, the industry circulated a "Letter from the Guangdong Provincial Medical Security Bureau on Jointly Procuring the Procurement of the Provincial Drug and Consumable Ultrasonic Blade Alliance"
.
Among the drugs that were collected by the central government involved "recombinant human growth hormone", the stock prices of related companies such as Changchun Hi-tech and Anke Biotech continued to fall
.
Behind these actions, we can also see that a big storm of biological medicine entering the centralized collection is brewing
.

       In response to the current situation of domestic competition, domestic pharmaceutical companies that produce bevacizumab have also prepared for a rainy day, for example, have begun to "go out to sea" one after another
.

       In January 2020, Cinda authorized Coherus Bioscences' commercialization rights in the United States and Canada; in January 2021, Cinda Biotech signed a cooperation agreement with Indonesian company Etana, granting Etana the exclusive license to Indonesia
.

       Before the product is on the market, Biotech also signed an agreement with BeiGene in August 2020 to license the intellectual property rights of BAT1706 (bevacizumab) and its product rights in China to BeiGene with a down payment.
The total amount of funds and milestones is up to 165 million U.
S.
dollars
.

       At present, three domestic bevacizumab companies have already gathered.
In the future, competing products such as Hengrui will be lined up for listing.
The pressure of related companies is self-evident.
If mass procurement is carried out, the hospital market is bound to usher in a major reshuffle
.
At this time, advance the layout of the out-of-hospital market or the wider county market, or go to the sea, to occupy a certain advantage, and also to resist unknown market risks
.